ATXI (Avenue Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)

What is Avenue Therapeutics Net Margin %?

Avenue Therapeutics ATXI +3.11% 31 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates ATXI with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Avenue Therapeutics ranks worse than 53.7% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Avenue Therapeutics's Net Income for the three months ended in Mar. 2026 was $-0.70 Mil. Avenue Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Avenue Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Avenue Therapeutics's Net Margin % or its related term are showing as below:

ATXI' s Net Margin % Range Over the Past 10 Years
Min: -207.19 Med: -207.19 Max: -124.79
Current: -124.79

ATXI's Net Margin % is ranked worse than
53.7% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs ATXI: -124.79

Avenue Therapeutics (OTCPK:ATXI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Avenue Therapeutics Net Margin % Related Terms

Avenue Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics Net Margin % Chart

Avenue Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

0.00

-207.19

Avenue Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.00	23.86	0.00	0.00	0.00

ATXI vs PTIX, EVFM, AGTX: Net Margin % Comparison

For the Biotechnology subindustry, Avenue Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avenue Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Net Margin % falls into.

Save Embed

31GF Score

Avenue Therapeutics Inc ATXI

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Avenue Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Avenue Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-2.909	/	1.404
	=	-207.19 %

Avenue Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-0.695	/	0
	=	%

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of 0.00% mean?

Avenue Therapeutics (ATXI) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Avenue Therapeutics and its competitors. According to the industry distribution chart, Avenue Therapeutics ranks #508 out of 946 companies in the Biotechnology industry, placing it in the top 53.7%.

Is Avenue Therapeutics' Net Margin % too high?

Avenue Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Avenue Therapeutics ranks #508 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Avenue Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Avenue Therapeutics' Net Margin % compare to PTIX and EVFM?

According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #508 out of 946 companies for Net Margin %. This places Avenue Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Avenue Therapeutics stock overvalued right now?

Avenue Therapeutics (ATXI) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Avenue Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avenue Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PTIX EVFM AGTX ABPO CERO EMMA LYRA ISCO ONCO VRAX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154

Website https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.

31GF Score

Get the complete analysis for ATXI

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32

Price

View ATXI Analysis

See Net Margin % data for all stocks →